Latest news with #AP3
The Irish Sun
05-08-2025
- The Irish Sun
Full catalogue of failures in Titan sub disaster laid bare in new report… & ‘negligent' CEO Stockton Rush WAS to blame
DOOMED SUB Full catalogue of failures in Titan sub disaster laid bare in new report… & 'negligent' CEO Stockton Rush WAS to blame A DAMNING report into the doomed Titan sub has laid a bare catalogue of fatal failures and negligence that led to the deaths of five people. The bombshell file also points squarely at OceanGate CEO Stockton Rush as the man to blame for the 2023 disaster. Advertisement 3 Damning report into doomed sub tragedy finds catastrophe was 'preventable' and down to a deadly cocktail of errors Credit: AP 3 The 335-page investigation, released Tuesday by the US Coast Guard, concludes the tragedy was "preventable" and driven by "critically flawed" practices, design shortcuts, and an appalling safety culture inside the deep-sea tourism company. Rush, who died in the implosion along with four passengers near the wreck of the Titanic, was found to have "exhibited negligence that contributed to the deaths of four individuals", according to the report. In a stinging assessment, investigators said had Rush survived, they would have recommended the Department of Justice consider a criminal probe. The report stated: "For several years preceding the incident, OceanGate leveraged intimidation tactics, allowances for scientific operations, and the company's favourable reputation to evade regulatory scrutiny. Advertisement "By strategically creating and exploiting regulatory confusion… OceanGate was ultimately able to operate Titan completely outside of the established deep-sea protocols." More to follow... For the latest news on this story, keep checking back at The U.S. Sun, your go-to destination for the best celebrity news, sports news, real-life stories, jaw-dropping pictures, and must-see videos. Like us on Facebook at TheSunUS and follow us on X at @TheUSSun 3
The Irish Sun
07-07-2025
- Sport
- The Irish Sun
Novak Djokovic gets away with X-rated outburst as Wimbledon crowd left in stunned silence
NOVAK DJOKOVIC launched a foul-mouthed tirade as he struggled with conditions on Centre Court against Alex de Minaur. The Serb was not at the races as Advertisement 3 Novak Djokovic was furious as he struggled with the conditions at Wimbledon Credit: BBC 3 The Serb made a dismal start and looked uncomfortable for much of the match Credit: AP 3 Djokovic touched his chest as he went to change his shirt during a break in play Credit: AFP Djokovic then took an attritional second set 6-4 to level the match, while still appearing to struggle with the wind. And frustrations boiled over in the third when the seven-time champion placed an easy-looking return well out of play. He then launched a foul-mouthed tirade at the top of his voice in his native Serbian. The Serb was accused by fans of saying: "F*** you, f*** you, what a f***ing spin." Advertisement READ MORE WIMBLEDON NEWS There were audible gasps from the crowd before hushed silence set in with fans on Centre Court - despite probably not being able to understand what he said - being surprised at the sheer volume of his outburst. One Djokovic fan took to X to say: "Hahahahahaha I am not feeling well.." While a detractor posted: "This is why Djokovic isn't nearly as respected as his peers..." If the umpire had understood what Djokovic had said, he would have picked up a code violation and been warned for the misdemeanour. Advertisement Most read in Sport Comment BEST ONLINE CASINOS - TOP SITES IN THE UK In the event of a second code violation, players are forced to forfeit a point, followed by a game for a third and finally, the match for a fourth. In a tongue-in-cheek interview in 2023, Djokovic told Eurosport that he was trying to work out new ways of swearing in his own language to avoid falling foul of umpires. Novak Djokovic explains new Wimbledon celebration after playing violin for daughter last year He said: "The problem we have, because of the success of Croatian and Serbian players in the last 30 years or so, we unfortunately have a situation where most of the umpires understand the swearing words. Advertisement "So we have to play around a little bit, we have to use the slang, create new words, but when you're p***ed off you don't think about creating."
New York Post
20-06-2025
- Politics
- New York Post
Andrew Cuomo racks up Democratic power player Rep. Jim Clyburn's endorsement in NYC mayoral race
Democratic kingmaker Rep. Jim Clyburn endorsed Andrew Cuomo in the Big Apple's mayoral primary Friday — as surging socialist contender Zohran Mamdani's campaign garnered a mix of fresh condemnation and support. Clyburn, the 84-year-old South Carolina congressman, cast Cuomo as a bulwark against President Trump and asserted the former governor and accused sex pest has the 'experiences, credentials and character to not just serve New York, but also save the nation.' 'The mayor of New York is uniquely positioned to play an important role in the future of the national Democratic Party,' Clyburn said in a statement. 3 Rep. James Clyburn on Friday endorsed Andrew Cuomo in the Democratic mayoral primary. AP 3 Cuomo is the mayoral frontrunner in the polls. Stephen Yang Cuomo, 67, has vigorously denied the sexual harassment accusations against him. He responded to Clyburn's endorsement with a backhanded jab at the 33-year-old Mamdani's arguably pie-in-the-sky campaign promises. '(Clyburn) has always been on the right side of history, and he has spent a lifetime prioritizing making real change over headlines, of action over words, and results over performative politics,' Cuomo wrote on X. Clyburn is widely credited with rescuing Joe Biden's then-flailing presidential bid in 2020. His endorsement of Cuomo, first reported by The New York Times, could help the thrice-elected Democrat further solidify the support of black New Yorkers. According to a recent poll, nearly half of black voters backed the governor in the June 24 Democratic mayoral primary, comparted to 11% support for Mamdani and 12% for City Council Speaker Adrienne Adams. But Mamdani arguably got a half-hearted boost from Adams, as the black lawmaker from southeast Queens on Friday endorsed the Working Families Party slate of candidates. The progressive party's slate picked Mamdani first in their ranked-choice endorsements, followed by City Comptroller Brad Lander, Adams and state Sen. Zellnor Myrie. The moderate Adams, however, conspicuously avoided naming Mamdani and explicitly said she wouldn't cross-endorse any candidates. She instead argued Cuomo should not be mayor. 'That's why, in addition to ranking me number one, I encourage New Yorkers to rank the full slate of Working Families Party candidates. We don't agree on everything – and if we did, I wouldn't be running. But I believe they care deeply about this city and its future. They have principles.' 3 Zohran Mamdani received the implicit backing of rival Adrienne Adams in the ranked-choice primary. Paul Martinka Mamdani, a state Assemblyman from Queens, also recently wracked up the endorsement of outspoken progressive former Assemblywoman Yuh-Line Niou. But another of Mamdani's Albany colleagues — state Assemblyman Jeffrey Dinowitz (D-Bronx) — strongly urged voters not to rank the socialist firebrand, alleging his 'fanatical hatred of Israel' is disqualifying to lead a city with a large Jewish population.
New York Post
29-04-2025
- New York Post
3 people dead after shooting in Uppsala, Sweden: police
Swedish police said that three people are confirmed dead after a shooting on Tuesday in Uppsala, a city near Stockholm, and are 'investigating the incident as a murder.' Police said in a statement that they had received calls from members of the public who reported hearing loud bangs reminiscent of gunfire in central Uppsala. 3 Swedish police said that three people are confirmed dead after a shooting on Tuesday in Uppsala, a city near Stockholm, and are 'investigating the incident as a murder.' AP 3 Police said they had received calls from members of the public who reported hearing loud bangs reminiscent of gunfire in central Uppsala. AP 3 Police at the scene after a shooting incident, at Vaksala Square, in central Uppsala, Sweden, on April 29. AP A large area was cordoned off by police as they launched an investigation. There was no immediate indication of motive, and the police statement did not provide details about a suspected perpetrator. But Swedish broadcaster SVT reported that the perpetrator fled the crime scene on an electric scooter.
Yahoo
19-03-2025
- Business
- Yahoo
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316 WATERTOWN, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ('Acrivon' or 'Acrivon Therapeutics') (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, announced it will be holding a virtual R&D event on March 25, 2025 from 4:00 p.m. to 5:15 p.m. ET. The agenda will feature presentations by Acrivon's leadership and founding team and endometrial cancer key opinion leaders, followed by a Q&A session. Key Opinion Leader Participants: Mansoor Raza Mirza, M.D., chief oncologist at Copenhagen University Hospital, Denmark; medical director of the Nordic Society of Gynecologic Oncology-Clinical Trial Unit (NSGO-CTU); vice president of the European Society of Gynecological Oncology (ESGO); board of directors, Gynecologic Cancer Inter-Group (GCIG) Robert L. Coleman, M.D., co-director of the Gynecologic Oncology Group (GOG) Partners Foundation, Inc.; chief medical officer at Vaniam Group Jesper Olsen, Ph.D., professor at the University of Copenhagen; deputy director at the Novo Nordisk Foundation Center for Protein Research; academic co-founder of Acrivon A live webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company's website at The webcast will be available for at least 30 days following the event. About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner yielding terabytes of high resolution proprietary quantitative data for pathway-based drug design, indication finding, and response prediction. These distinctive capabilities enable AP3's direct application for streamlined rational drug discovery for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon's drug candidates. Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon's ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designations for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer or for patients with ovarian cancer, who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company's second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as demonstrated in preclinical studies against benchmark inhibitors. In addition, the company has a preclinical cell cycle program with an undisclosed target. Acrivon has developed its AP3 Interactome, a proprietary, computational analytics platform driven by Generative Phosphoproteomics machine learning for integrated comprehensive analyses across all large, in-house AP3 phosphoproteomic drug profiling data sets to advance its in-house research programs. Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law. Investor and Media Contacts: Adam D. Levy, Ph.D., Alexandra Santos asantos@ in to access your portfolio
